Outcome of different types of long-term antidepressant treatments: A 3-year follow-up study of 14,182 patients

Journal of Affective Disorders

Volumn 55, Issue 1, 1999, Pages 67-71

  Räsänen, Pirkko ^a   Hakko, Helinä ^a   Jokelainen, Jari ^a   Tiihonen, Jari ^b,c  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Antidepressant; Disability pension; Efficacy; Treatment

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; MIANSERIN; MOCLOBEMIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; FEMALE; FINLAND; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PENSION; POPULATION RESEARCH; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK FACTOR; SOCIAL DISABILITY;

ADULT; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; FEMALE; FLUOXETINE; FOLLOW-UP STUDIES; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0344199957     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(99)00002-6     Document Type: Article

References (13)

1. Burrows, G.D., Kremer, C.M., 1997. Mirtazapine: clinical advantages in the treatment of depression. J. Clin. Psychopharmacol. 17 (2), 34S-39S.
2. Cohen, L.J., 1997. Rational drug use in the treatment of depression. Pharmacother. 17, 45-61.
3. Fabre, L., Birkhimer, L.J., Zaborny, B.A., Wong, L.F., Kapik, B.M., 1996. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients. Int. Clin. Psychopharmacol. 11, 119-127.
4. Fulton, B., Benfield, B., 1996. Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs 52, 450-474.
5. Hotopf, M., Hardy, R., Lewis, G., 1997. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br. J. Psyhciatry 170, 120-127.
6. Kasper, S., 1997. Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. J. Clin. Psychopharmacol. 17 (2), 19S-28S.
7. Kernick, D.P., 1997. Which antidepressant? A commentary from general practice on evidence-based medicine and health economics. British Journal of General Practice 47, 95-98.
8. Montgomery, S.A., Dufour, H., Brion, S., Gailledreau, J., Laqueille, X., Ferrey, G., Moron, P., ParantLucena, N., Singer, L., Danion, J.M. et al., 1988. The prophylactic efficacy of fluoxetine in unipolar depression. Br. J. Psychiatry 153, 69-76.
9. Montgomery, S.A., Henry, J., McDonald, G., Dinan, T., Lader, M., Hindmarch, I., Clare, A., Nutt, D., 1994. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int. Clin. Psychopharmacol. 9, 47-53.
10. Montgomery, S.A., Kasper, S., 1995. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int. Clin. Psychopharmacol. 9 (Suppl 4), 33-40.
11. Preskorn, S.H., 1997. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin. Pharmacokinetics 32 (Suppl. 1), 1-21.
12. Räsänen, P., Hakko, H., Tiihonen, J. Pindolol and major affective disorders: a three-year follow-up study of 30485 patients. J. Clin. Psychopharmacol., in press.
13. Song, F., Freemantle, T.A., House, A., Watson, P., Long, A., Mason, J., 1993. Selective serotonin reuptake inhibitors: metaanalysis of efficacy and acceptability. Br. Med. J. 306, 683-687.